

## Resveratrol for the Management of Diabetes and its Downstream Pathologies

Moola Joghee Nanjan<sup>1</sup> and James Betz<sup>2</sup>

1. Director, Research JSS College of Pharmacy, Ootacamund, India; 2. Chief Science Officer, Biotivia Labs LLC, Arlington, Virginia, US

### Abstract

Over the past 10 years more than 10,000 papers and *in vitro* investigations have been published that identify or analyse various critical pathways and biological processes through which the phytoalexin resveratrol has been shown to attenuate the metabolic dysfunctions, acute symptomatology and the consequential downstream pathologies related to type 2 diabetes. More recently, several clinical trials have confirmed resveratrol's potential to substantially enhance the therapeutic effects of the pharmaceutical metformin hydrochloride, particularly related to glucose management, insulin sensitivity and cardioprotection. Metformin is the most commonly prescribed type 2 diabetes treatment worldwide; consequently, any compound with the ability to safely and effectively augment its therapeutic effects warrants intensive investigation. This paper elucidates the principal modes of action that underly resveratrol's promising potential as an effective adjunct treatment for patients currently being administered metformin.

### Keywords

Resveratrol, diabetes, diabetes management, metformin, metformin adjunct, glucose homeostasis, cardiovascular protection, adjuvant therapy

**Disclosure:** Moola Joghee Nanjan has no conflicts of interest to declare. James Betz is an employee of Biotivia Labs LLC.

**Received:** 24 January 2014 **Accepted:** 12 March 2014 **Citation:** *European Endocrinology*, 2014;10(1):31–5 DOI:10.17925/EE.2014.10.01.31

**Correspondence:** James Betz, Chief Science Officer, Biotivia Labs LLC, 2503 D North Harrison St, Arlington, Virginia 22207. US. E: james.betz@gmail.com

**Support:** The publication of this article was supported by Biotivia.

Diabetes is a metabolic disorder, characterised by hyperglycaemia and associated disturbances, which results from defects in insulin secretion, action or a combination of both. Type 1 diabetes is associated with complete or relative insulin deficiency related to autoimmune-mediated destruction of pancreatic  $\beta$ -cells. Type 2 diabetes is associated with variable degrees of insulin resistance, impaired insulin secretion, moderate to severe  $\beta$ -cell apoptosis and increased hepatic glucose production.<sup>1</sup> Insulin and glucagon are the primary hormones that maintain glucose homeostasis by controlling its concentration in blood. When the blood glucose level increases, insulin-mediated signalling lowers it by enhancing glucose uptake in the skeletal muscle, adipose tissue and kidneys, and by promoting its utilisation and storage in the liver. When the blood glucose level decreases, glucagon raises it by promoting glucose production and release in the liver, and by increasing lipolysis from adipose tissue. Compounds that target glucose-regulating processes in the pancreas, liver, skeletal muscles and adipose tissues can, therefore, affect glucose homeostasis.<sup>2</sup> Insulin and oral anti-diabetic agents including sulphonylureas, biguanides, thiazolidinediones and  $\alpha$ -glucosidase inhibitors, are the conventional pharmaceutical agents used to treat diabetes.<sup>3</sup> All these hypoglycaemic agents, however, have adverse side effects of varying severity and only alleviate symptoms, while failing to target their cause. Efforts have been made in recent years to identify natural compounds that may promote glucose homeostasis through regulation and modulation of cellular and extracellular pro-diabetic biochemical, nutritional, epigenetic and enzymatic pathways, processes and effects, without associated adverse reactions. In this connection, resveratrol, a naturally occurring polyphenol, has been widely studied for its beneficial effects in maintaining glucose homeostasis, and

hence treating diabetes and its accompanying complications. The *in vitro* and *in vivo* evidence underlying resveratrol's ability to attenuate blood glucose levels and reduce hypertension, inhibit insulin resistance and beneficially modify the ratio of plasma high-density lipoproteins (HDLs) to low-density lipoproteins (LDLs) and triglycerides, clearly identify this compound as a potentially effective and safe adjunct treatment of type 2 diabetes for patients who are being treated with metformin and related glucophage-type drugs, as well as those who manage their symptoms primarily by dietary strategies and regular physical exercise.

### What is Resveratrol?

Resveratrol, trans-3,5,4-trihydroxystilbene, is a naturally occurring phytoalexin produced by certain spermatophytes in response to injury.<sup>4</sup> Grape vines, berries and peanuts are dietary sources of this compound, with good concentrations in the leaf epidermis and skin of grape berries.<sup>5,6</sup> The principal natural source for commercial extraction of resveratrol is the Japanese giant knotweed, or *polygnum-cuspidatum* plant rhizome. Resveratrol can also be obtained by synthesis in the laboratory, and can occur in multiple forms. The *l*ioforms, trans and cis, exhibit different biological properties. The trans conformation possesses numerous well-established health benefits. Less is known about the cis isomer; however, it has not been as widely associated with potential disease chemoprevention and treatment.

Resveratrol is rapidly absorbed from the intestine, allowing its distribution, primarily in the liver, kidneys, brain, lungs and muscles. Removal of

**Table 1: Resveratrol and the Management of Diabetes – Cell Culture and Animal Studies**

Ref.	Model and Period	Parameters Analysed	Results and Conclusions
20	<i>In vitro</i> mouse 3T3–L1 adipocyte cell culture; <i>in vivo</i> male rhesus monkey; (2-year period)	Total cholesterol, LDL-C and HDL-C; protein extraction; Western blot and immunoprecipitation; gene expression; histology; immunocytochemistry; enzyme-linked immunosorbent assay; citrate synthase activity and hydrogen peroxide determination	↓ Adipocyte size, ↑ SIRT1 expression, ↓ NF-κB activation and improves insulin sensitivity in visceral WAT from HFS-fed animals
21	<i>In vivo</i> SD rats; STZ-induced type 2 diabetes model; dose 40 mg/kg IP; (24-week period)	Vascular permeability assay; histological examinations; immunohistochemical staining; qRT-PCR analysis; Western blot analysis; cell culture and viability assay; inhibition of NF-κB p65 activation by small interfering RNA and PDTC in cultured endothelial cells	↓ NF-κB, ↓ IL-1β and ↓ IL-6 in blood; ↓ TNFα, ↓ ICAM-1 and ↓ MCP-1 expressions in vascular wall
22	<i>In vitro</i> RINm5F pancreatic cells from MG-induced apoptosis	ROS measurement; assay for cell apoptosis; Western immunoblotting; detection of insulin protein expression in RINm5F cells	Inhibits MG-mediated expression of CCAAT/enhancer-binding protein C/EBP-β activates the expression of Nrf2
23	<i>In vitro</i> cell culture-3T3-L1 pre-adipocytes; <i>in vivo</i> C57BL/6J female mice; diet regulation; (6-week period)	Oil red O staining; RT-PCR; glucose uptake into C2C12 cells; Western blot analysis; oral GTT; ITT; measurement of glucose uptake into skeletal muscle	Inhibits adipocyte differentiation, ↑ glucose uptake in the myotubes
24	<i>In vivo</i> male, 5-week-old db/db and db/dm (non-diabetic control) mice (12-week period)	GTT and ITT; immunohistochemical staining; Masson's trichrome staining; beta-cell mass in pancreatic islet; plasma and urinary ROS markers	Improves glucose tolerance at 2 hours in db/db mice; ↑ pancreas weight and beta-cell mass; ↓ islet fibrosis and urinary 8-OHdG levels
25	<i>In vivo</i> male C57BL/6J mice; (24-week period)	Isolation and batch incubation of islets, morpho metric evaluation; pancreatic insulin content; apoptosis by TUNEL TG measurements in pancreas; RT-PCR; IPGTTs; analysis of protein expression by Western blot analysis; oxidative stress damage	↓ The levels of glucose, ↓ lipid metabolism, ↓ beta cell mass, ↓ lipid content, ↓ oxidative stress; promotes SIRT1 expression islets; beneficial effect on the ratios of expressions of Bcl-2/Bax and levels of malondialdehyde/↑ glutathione peroxidase
26	<i>In vitro</i> mesangial cells-glomeruli of SD rats	SIRT1 activity assessment; Western blot analysis; intracellular ROS assay; mitochondrial superoxide generation determination; MnSOD activity assay; determination of activities of mitochondrial complexes I and III; measurement of mitochondrial membrane potential; ATP content determination; MtDNA content detection	↓ Hyperglycaemia-induced increase in ROS production and mitochondrial superoxide generation and stimulates MnSOD activity; reverses the mitochondrial complex III activity and restores the hyperpolarisation of Δψm, ↑ ATP production and preserve the mtDNA content
27	<i>In vivo</i> STZ-induced model; male wistar rats; dose 55 mg/kg IP; (30-day period)	Blood glucose and body weight; determination of lipid peroxidation; CAT and SOD activities; vitamin C NPSH content; δ-ALA-D; biochemical analysis; protein determination	Prevents the ↑ CAT, ↑ SOD and ↑ δ-ALA-D and the levels of nonprotein thiols and vitamin C; ↓ serum ALT, ↓ AST and ↓ rGT activities, ↓ levels of urea, ↓ creatinine, ↓ cholesterol and triglycerides (to normal levels)
28	<i>In vitro</i> cell culture THP-1 cell line	Trypan blue exclusion assay; immunostaining; preparation of nuclear fraction; measurement of HDAC activity using ELISA; Western blot analysis; measurement of intracellular superoxide production; small interfering RNA transfection assays	↓ HG-induced superoxide production via upregulation of SIRT1, induction of FOXO3a and inhibition of p47phox in monocytes
29	<i>In vivo</i> male SD rats; STZ-induced model (8-week period)	Plasma biochemistry; isolation of glomeruli; assessment of kidney morphology and estimation of glomerular volume by light microscopy; immunohistochemical staining for TGF-β1, fibronectin and collagen IV in glomeruli; Western blot analysis; electron microscopy	Urinary albumin excretion, glomerular hypertrophy and expressions of fibronectin, collagen IV and TGF-β in the glomeruli were alleviated; ↓ the thickness of the glomerular basement membrane to the original thickness; ↑ Increases nephrin expressions to normal levels; Inhibits phosphorylation of smad2, smad3 and ERK1/2 in diabetic rat kidneys

8-OHdG = 8-hydroxy-2'-deoxyguanosine; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ATP = adenosine triphosphate; CAT = catalase; δ-ALA-D = delta-aminolevulinic acid dehydratase; ELISA = enzyme linked immunosorbent assay; ERK1/2 = extracellular signal-regulated protein kinases 1/2; GTT = glucose tolerance test; HDAC = histone deacetylase; HDL-C = high-density lipoprotein cholesterol; HFS = high fat sucrose; HG = high glucose; ICAM-1 = intercellular adhesion molecule-1; IL = interleukin; IPGTT = intraperitoneal glucose tolerance test; IP = intraperitoneal; ITT = insulin tolerance test; IV = intravenous; LDL-C = low-density lipoprotein cholesterol; MCP-1 = monocyte chemoattractant protein 1; MG = methylglyoxal; MnSOD = manganese superoxide dismutase; MtDNA = mitochondrial DNA; NF-κB = nuclear factor kappaB; NPSH = non protein thiol; PDTC = pyrrolidine dithiocarbamate; qRT-PCR = quantitative reverse transcription polymerase chain reaction; rGT = r-glutamyltranspeptidase; SD = Sprague Dawley; RNA = ribonucleic acid; ROS = reactive oxidative stress; RT = real time; SIRT1 = sirtuin 1; SOD = superoxide dismutase; STZ = streptozotocin; TG = triglyceride; TGF-β1 = transforming growth factor beta 1; TNFα = tumour necrosis factor-alpha; TUNEL = terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; WAT = white adipose tissue.

resveratrol from the body occurs mainly through renal excretion. Resveratrol is known to impact numerous mechanisms and pathways within the body, including inhibition of lipid peroxidation, free radical scavenging, alteration of eicosanoid synthesis, modulation of lipid metabolism, improvement of insulin sensitivity, anti-inflammatory activity, signalling pathways, mitochondrial processes and both pro-oestrogenic and anti-oestrogenic activity.<sup>7-9</sup>

### Resveratrol and Diabetes

The exact cellular and molecular mechanism of the aetiology and the progression of diabetes is still not fully understood. There is increasing evidence, however, that oxidative stress plays a crucial role in the

pathogenesis of diabetes and its complications, and that the β-cell dysfunction is closely related to it and possibly exacerbated by the weakened antioxidant defense of the pancreatic islets.<sup>10</sup> Among other activities, resveratrol has been reported to possess potent antioxidant properties,<sup>11-14</sup> and so it has become an attractive therapeutic agent in the treatment of diabetes and its associated complications. The first known use of grape extract for the benefit of human health dates back over 3,000 years. Drakshasava, an Ayurvedic medicine whose main constituent is *vitis vinifera* L, is prescribed as a cardi tonic in India:<sup>15</sup> a major portion of this extract is resveratrol. In addition to its antioxidant properties, resveratrol appears to beneficially modulate an array of

**Table 2: Resveratrol and the Management of Diabetes – Clinical Studies**

Ref	Cohort (n)	Form of RSV and Duration	Dose and Schedule	Conclusions
31	Type 2 diabetes patients with hypertension (35)	RSV-enriched grape extract capsule; 1 year	8 mg/day to 16 mg/day; 1 per day for first 6 months; 2 per day for last 6 months	Long-term supplementation with a grape extract containing resveratrol downregulates the expression of key pro-inflammatory cytokines with the involvement of inflammation-related miRNAs in circulating immune cells of hypertensive-medicated patients with type 2 diabetes and supports beneficial immunomodulatory effect
32	Type 2 diabetes patients (66)	Capsule; 45 days	1 g/day; 500 mg/day twice daily	↓ Systolic blood pressure, ↓ fasting blood glucose, ↓ HbA <sub>1c</sub> , ↓ insulin and ↓ insulin resistance ↑ HDL level
33,34	Type 2 diabetes patients (62)	Capsule; 3 months	250 mg/day; single	↓ HbA <sub>1c</sub> , ↓ systolic blood pressure, ↓ body weight lipid profile and total protein in type 2 diabetes
35	Type 2 diabetes patients (19)	Capsule; 4 weeks	10 mg/day; 5 mg/day twice daily	↓ Insulin resistance, ↓ urinary ortho-tyrosine excretion; ↑ pAkt:Akt ratio in platelets

Akt = protein kinase B; HbA<sub>1c</sub> = glycated haemoglobin; HDL = high-density lipoprotein; miRNAs = microRNAs; pAkt = phosphorylated protein kinase B; RSV = resveratrol.

biological mechanisms at the cellular and extracellular levels that have been identified as having chemopreventive properties with respect to a significant number of chronic diseases, particularly those commonly associated with ageing and obesity.<sup>16,17</sup> Moreover, resveratrol's ability to activate sirtuins 1–7 (SIRT1–7), particularly SIRT1, a prolific, highly conserved NAD<sup>+</sup>-dependent lysine deacetylase,<sup>18</sup> either indirectly via the intermediary coenzyme NAD<sup>+</sup> at low doses, or directly at high doses, identifies this molecule as a prime candidate for adoption as a potential pharmacological agent targeted towards the cellular and extra-cellular dysfunctions and abnormalities underlying type 2 diabetes, obesity and other mitochondrial-mediated metabolic pathologies. Given the low level of patient compliance with behaviour-modification-based type 2 diabetes remedial strategies, such as diet and regular vigorous physical exercise,<sup>19</sup> clearly there exists a mandate for development of non-toxic, efficacious and affordable treatments to stem the accelerating escalation in the incidence of this disease worldwide.

Table 1 summarises some of the recent cell culture and animal studies that have been undertaken on the benefits of treating diabetes and its accompanying complications with resveratrol. The data clearly reveal several clinically relevant aspects. Among the major findings are that chronic resveratrol administration provides a safe approach to reduce chronic inflammatory properties associated with obesity while restoring insulin responsiveness in visceral white adipose tissue (WAT),<sup>20</sup> attenuates the inflammatory injury of the vascular wall,<sup>21</sup> attenuates methylglyoxal (MG)-induced oxidative stress in pancreatic cells with increase in insulin levels,<sup>22</sup> reduces oxidative-stress obesity pathologies and improves glucose tolerance.<sup>23</sup> Resveratrol attenuates β-cell loss, inhibits oxidative stress, improves glucose tolerance,<sup>24</sup> decreases plasma glucose levels, potentiates lipid metabolism, improves β-cell mass lipid content and diminishes oxidative stress, in addition to promoting SIRT1 expression. Furthermore, resveratrol effectively reduces reactive oxidative stress (ROS) and maintains mitochondrial function and enhances mitogenesis via SIRT1 activation. This extensive constellation of actions elucidate resveratrol's promise as a pharmacological agent to treat diabetic nephropathy,<sup>14–26</sup> protect against hepatic and renal damage induced by oxidative stress,<sup>27</sup> mediate high-glucose (HG)-induced superoxide production, modulate FOXO3a expression and protect p47phox monocytes against oxidative stress in HG conditions.<sup>28</sup> Resveratrol restores the diminished expression of nephrin in the kidneys of people with diabetes to normal levels and decreases plasma glucose levels, lipid metabolism, β-cell mass lipid content and oxidative stress damage, in addition to promoting SIRT1 expression islets. Resveratrol could thus be a new therapeutic agent for

retarding the progression of early diabetic nephropathy.<sup>29</sup> It also shows hepatocyte-protection activity through the attenuation of the markers of hyperglycaemia-mediated oxidative stress without affecting normal cellular function and structural integrity.<sup>30</sup>

Table 2 summarises the clinical studies that have been carried out so far on the benefits of resveratrol in treating diabetes and its accompanying complications, as well as studies in obese patients who are at risk of type 2 diabetes. The data reveal that long-term supplementation with grape extract containing a small quantity of resveratrol has a beneficial immunomodulatory effect on hypertensive patients with type 2 diabetes.<sup>31</sup> Resveratrol supplementation has benefits in type 2 diabetes patients, including lowering of blood glucose, glycated haemoglobin (HbA<sub>1c</sub>), insulin levels, insulin resistance and the improvement of HDL levels and fasting blood glucose.<sup>32</sup> Resveratrol supplementation has also been shown to reduce body weight, lower systolic blood pressure and to beneficially moderate total cholesterol, HDL:LDL ratios and to lower triglycerides and urea nitrogen. It also significantly increases the levels of endogenous antioxidant enzymes,<sup>33,34</sup> lowers insulin resistance and urinary ortho-tyrosine excretion and increases the platelet ratio of phosphorylated protein kinase B (pAkt) protein to kinase B (Akt) protein (pAkt:Akt). Akt is a serine-threonine kinase that mediates a number of cellular processes including vascular endothelial growth factor (VEGF) expression and insulin sensitivity by improving insulin signalling. Resveratrol is also associated with improvements in glycaemic and lipid parameters in obese individuals.<sup>32–35</sup>

Resveratrol modifies adipokine expression via inhibition of the inflammatory response, thereby reducing insulin resistance by activating SIRT1, which is the principal modulator that produces a beneficial effect on glucose homeostasis and insulin sensitivity.<sup>36</sup> It also restores endogenous antioxidant manganese superoxide dismutase (MnSOD) function independent of sirtuin activation.<sup>12</sup> Resveratrol appears to lower insulin resistance via the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a redox-sensitive transcription factor and peroxisome proliferator-activated receptor gamma (PPARγ). Resveratrol's inhibition of NF-κB operates to downregulate the pancreatic β-cell apoptotic pathway resulting in improved β-cell survival,<sup>37</sup> and exhibits an antioxidant independent protective effect against diabetic neuropathy.<sup>38</sup>

Resveratrol increases NAD<sup>+</sup> levels via upregulation of the NAD<sup>+</sup> synthetic enzyme nicotinamide mononucleotide adenylyltransferase.<sup>39</sup> Maintaining physiological NAD<sup>+</sup> levels is essential for normal cellular

respiratory functions, and may constitute an important mechanism by which resveratrol modulates metabolic homeostasis and supports mitochondrial biogenesis.<sup>40</sup>

At moderate to high concentrations, resveratrol is an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) also known as FK506 binding protein, 12-*rapamycin* associated protein 1 and FRAP1.<sup>41</sup> Although the full range of effects of mTORC1 activity on adult metabolic disorders, including type 2 diabetes, is an exceedingly complex matter, it does appear, based on some *in vivo* evidence, that inhibition of mTORC1 plays a constitutive role in the beneficial attenuation of insulin resistance and diabetic nephropathy.<sup>42,43</sup>

## Resveratrol and Cardiovascular Protection

Resveratrol, as a component, is believed to be responsible for the 'French Paradox', namely low mortality due to coronary heart disease as a result of moderate consumption of red wine by the French. Both the preclinical and clinical data, shown in *Tables 1* and *2*, as well as a large and growing body of additional *in vitro* and *in vivo* evidence, clearly reinforce this theory and suggest that resveratrol also plays a crucial role in cardiovascular disease (CVD) protection.<sup>44,45</sup> Wine also contains a relatively high level of non-stilbene phytochemicals, which are thought to potentiate the beverage's chemo-preventative properties in terms of CVD and other chronic diseases often associated with ageing and obesity in the general population.

## Resveratrol and Diabetic Retinopathy

One of the more devastating pathophysiological sequelae of protracted glycaemic instability is the degradation of vision resulting from acute retinopathy. Retinopathy is one of the leading causes of blindness among adult populations worldwide.<sup>46</sup> The condition is characterised by the propagation of abnormal, profuse microvascularity and concurrent capillary fibrosis, which precipitate occlusion of the retina and optic disc. Overexpression of the angiogenesis regulator, VEGF, has been implicated as a major promoter in the proliferation of these dysfunctional vascular structures. Aberrant angiogenesis and macular oedema are cofactors principally responsible for the progressive loss of visual acuity, which can advance in a relatively brief time to blindness.<sup>47,48</sup> Inflammation also appears to play a significant contributory role in the development of retinal pathologies.<sup>49</sup>

Resveratrol is a non-invasive, multi-modal, chemo-preventative agent with the ability to prevent or impede the onset and development of diabetic retinopathy. Resveratrol attenuates the progression of retinopathy by suppressing angiogenesis,<sup>50,51</sup> inhibiting inflammation<sup>52</sup> and downregulating neuronal apoptosis.<sup>53</sup> In its capacity as a potent small molecule antioxidant, resveratrol counters oxidative stress.<sup>54</sup> Finally, this phytochemical operates to block the vascular lesions as well as the endothelial hyperpermeability, which cause capillary leakage and loss of pericytes.<sup>55,56</sup> Resveratrol's inhibition of VEGF appears to be one of the main modalities via which the molecule exerts a potentially therapeutic reduction of a number of the principal initiators and mediators of retinopathy.<sup>57</sup>

## Safety and Tolerability of Resveratrol

Resveratrol is well tolerated in both young and older humans, and does not cause any serious adverse effects in subjects on doses of up to 5 g per day. Neither have toxicity or adverse effects been observed at higher

doses; however, limited data exist upon which to base any definitive conclusions relative to doses higher than 5 g per day. It is safe as revealed by lack of serious adverse events detected by clinical, biochemical and haematological indices during intervention and a two-week follow up.<sup>58,59</sup> Nearly 90 % of all reported adverse effects can be classified as grades 1 or 2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), with many being mild and transient.

## Conclusion

Resveratrol has been shown to be effective in modulating blood glucose levels, decreasing insulin resistance, inhibiting chronic inflammation, improving blood lipid profiles, attenuating diabetic hypertension and countering oxidative stress. Resveratrol may also play a role in the prevention or retardation of diabetes-related comorbidities and complications.

The biological processes, signalling pathways, proteomics and biochemical modalities via which resveratrol operates have been extensively investigated and are relatively well identified and defined. The therapeutic effects of this phytoalexin appear to include a significant improvement of an array of relevant metrics including improvement of insulin sensitivity, modulation of blood glucose levels, cardiovascular protection, attenuation of diabetic hypertension, inhibition of oxidative stress and chronic inflammation, improvement of blood lipid profiles and support of retinal health.

Major challenges remain concerning the safety and efficacy of chronic resveratrol administration as well as optimal doses, due to the well-known hormetic actions of the compound, which demonstrates protective properties at lower doses and detrimental effects at higher doses. Furthermore, although resveratrol administration shows beneficial effects, its molecular mechanisms of action are only partially known. It is well known that resveratrol is rapidly metabolised and conjugated with glucuronic acid and sulphate due to the action of uridine 5'-diphospho-glucuronosyltransferase (UDP-glucuronosyl-transferase) and sulphotransferases and these are the major circulating forms of this molecule, both in humans and experimental models. However, the biological activity of these active metabolites needs to be elucidated fully. Indeed, the majority of *in vitro* available data have been obtained by employing the unconjugated form of resveratrol, at concentrations that largely exceed those that can be reached *in vivo*, at both plasma and tissue levels.

Additional clinical trials are required to better elucidate the optimum dosages, delivery mechanisms and optimally efficacious drug-resveratrol combinations, as well as the qualitative nature of the potential long-term benefits associated with this compound as a nutraceutical adjunct to existing diabetes treatment stratagems.

Given the absence of observed adverse effects attributed to this compound after more than 10 years of investigation, coupled with clinical evidence of its efficacy and safety, the use of resveratrol as a nutritional supplement is well justified in patients with type 2 diabetes. A case now exists to support the enhancement of existing national healthcare systems' diabetes prevention and treatment programmes via augmentation with a resveratrol-based nutraceutical component. Healthcare practitioners should be aware of the potential benefits of resveratrol as an effective adjunct nutraceutical enhancement to patients with diabetes pharmaceutical and lifestyle-focused prevention and treatment stratagems. ■

- Akkati S, Sam KG, Tungha G, Emergence of promising therapies in diabetes mellitus, *J Clin Pharmacol*, 2011;51:796–804.
- Hanhineva K, Torronen R, Bondia-Pons I, et al., Impact of dietary polyphenols on carbohydrate metabolism, *Int J Mol Sci*, 2010;11:1365–402.
- Philippe J, Raccach D, Treating type 2 diabetes: how safe are current therapeutic agents?, *Int J Clin Pract*, 2009;63:321–32.
- de la Lastra CA, Villegas I, Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications, *Mol Nutr Food Res*, 2005;49:405–30.
- Donnez D, Jeandet P, Clement C, Courot E, Bioproduction of resveratrol and stilbene derivatives by plant cells and microorganisms, *Trends Biotechnol*, 2009;27:706–13.
- Baur JA, Sinclair DA, Therapeutic potential of resveratrol: the in vivo evidence, *Nat Rev Drug Discov*, 2006;5:493–506.
- Fremont L, Biological effects of resveratrol, *Life Sci*, 2000;66:663–73.
- Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta, *Endocrinology*, 2000;141:3657–67.
- Ruotolo R, Calani L, Fiotta E, et al., Anti-estrogenic activity of a human resveratrol metabolite, *Nutr Metab Cardiovasc Dis*, 2013;23:1086–92.
- Maritim AC, Sanders RA, Watkins JB 3rd, Diabetes, oxidative stress and antioxidants: a review, *J Biochem Mol Toxicol*, 2003;17:24–39.
- Giacco F, Brownlee M, Oxidative stress and diabetic complications, *Circ Res*, 2010;107:1058–70.
- Kitada M, Kume S, Imaizumi N, Koya D, Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway, *Diabetes*, 2011;60:634–43.
- Pandey KB, Rizvi SI., Anti-oxidative action of resveratrol: implications for human health, *Arabian J Chem*, 2011;4:293–8.
- Fabris S, Momo F, Ravagnan G, Stevanato R, Antioxidant properties of resveratrol and piceid on lipid peroxidation in micelles and monolamellar liposomes, *Biophys Chem*, 2008;135(1–3):76–83.
- Soleas GJ, Diamandis EP, Goldberg DM, Wine as a biological fluid: history, production, and role in disease prevention, *J Clin Lab Anal*, 1997;11:287–313.
- Crandall JP, Barzilai N, Exploring the promise of resveratrol: Where do we go from here?, *Diabetes*, 2013; 62:1022–3.
- Yu W, Fu YC, Wang W, Cellular and molecular effects of resveratrol in health and disease, *J Cell Biochem*, 2012;113:752–9.
- Tennen RI, Michishita-Kioi E, Chua KF, Finding a target for resveratrol, *Cell*, 2012;148:387–9.
- Nelson KM, Reiber G, Boyko EJ; NHANES III, Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III), *Diabetes Care*, 2002;25:1722–8.
- Jimenez-Gomez Y, Mattison JA, Pearson KJ, et al., Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet, *Cell Metab*, 2013;18:533–45.
- Zheng X, Zhu S, Chang S, et al., Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-kappa B signaling, *Eur J Pharmacol*, 2013;720:147–57.
- Cheng AS, Cheng YH, Chang TL, Resveratrol protects RINm5F pancreatic cells from methylglyoxal-induced apoptosis, *J Funct Foods*, 2013;5:1774–83.
- Ito-Nagahata T, Kurihara C, Hasebe M, et al., Stilbene analogs of resveratrol improve insulin resistance through activation of AMPK, *Biosci Biotechnol Biochem*, 2013;77:1229–35.
- Lee YE, Kim JW, Lee EM, et al., Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice, *PLoS ONE*, 2012;7:e50412.
- Zhang J, Chen L, Zheng J, et al., The protective effect of resveratrol on islet insulin secretion and morphology in mice on a high-fat diet, *Diabetes Res Clin Pract*, 2012;97:474–82.
- Xu Y, Nie L, Yin YG, et al., Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells, *Toxicol Appl Pharmacol*, 2012;259:395–401.
- Schmatz R, Perreira LB, Stefanello N, et al., Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta-aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats, *Biochimie*, 2012;94:374–83.
- Yun JM, Chien A, Jialal I, Devaraj S, Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights, *J Nutr Biochem*, 2012;23:699–705.
- Chen KH, Hung CC, Hsu HH, et al., Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF- $\beta$ /Smad and ERK1/2 signaling in streptozotocin-induced diabetic rats, *Chem Biol Interact*, 2011;190:45–53.
- Palsamy P, Sivakumar S, Subramanian S, Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats, *Chem Biol Interact*, 2010;186:200–10.
- Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, et al., One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease, *Pharmacol Res*, 2013;72:69–82.
- Movahed A, Nabipour I, Lieben Louis X, et al., Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients, *Evid Based Complement Alternat Med*, 2013;ID 851267.
- Bhatt JK, Thomas S, Nanjan MJ, Resveratrol supplementation improves glycemic control in type 2 diabetic mellitus, *Nutr Res*, 2012;32:537–41.
- Bhatt JK, Nanjan MJ, Resveratrol supplementation in patients with type 2 diabetic mellitus: a prospective, open label, randomized controlled trial, *Int Res J Pharm*, 2013;4:245–9.
- Brasnyó P, Molnár GA, Mohás M, et al., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients, *Br J Nutr*, 2011;106:383–9.
- Lagouge M, Argmann C, Gerhart-Hines Z, et al., Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 $\alpha$ , *Cell*, 2006;127:1109–22.
- Heimberg H, Heremans Y, Jobin C, et al., Inhibition of cytokine-induced NF-kappaB activation by adenovirus-mediated expression of a NF-kappaB super-repressor prevents beta-cell apoptosis, *Diabetes*, 2001;50:2219–24.
- Kumar A, Sharma SS, NF- $\kappa$ B inhibitory action of resveratrol: A probable mechanism of neuroprotection in experimental diabetic neuropathy, *Biochem Biophys Res Commun*, 2010;394:360–5.
- Grant R, Resveratrol Increases Intracellular NAD<sup>+</sup> Levels Through Up regulation of The NAD<sup>+</sup> Synthetic Enzyme Nicotinamide Mononucleotide Adenylyltransferase. Available from Nature Precedings: <http://hdl.handle.net/10101/npre.2010.4421.1> (2010): <http://precedings.nature.com/documents/4421/version/1> (accessed 27 March 2014).
- Canto C, Auwerx J, NAD<sup>+</sup> as a signaling molecule modulating metabolism, *Cold Spring Harb Symp Quant Biol*, 2011;76:291–8.
- Liu M, Wilk SA, Wang A, et al., Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR, *J Biol Chem*, 2010;285:36387–94.
- Minton K, Metabolism: Role for mTORC2 in insulin resistance, *Nat Rev Mol Cell Biol*, 2013;14:67.
- Lloberas N, Cruzado JM, Franquesa M, et al., Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats, *J Am Soc Nephrol*, 2006;17:1395–404.
- Catalgol B, Batirel S, Taga Y, Ozer NK, Resveratrol: French paradox revisited, *Front Pharmacol*, 2012;3:141.
- Kopp P, Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? *Eur J Endocrinol*, 1998;138:619–20.
- Bourne RR, Stevens GA, White RA, et al., Causes of vision loss worldwide, 1990–2020: a systematic analysis, *Lancet Global Health*, 2013;1(6):e339–49.
- Ventura AA, Dadgostar H, Taban M, Diabetic Retinopathy. In Bandeira F, Gharib H, Golbert A, et al., (eds) *Endocrinology and Diabetes, A Problem-Oriented Approach*, Springer Science & Business Media, New York, 2014;475–80.
- Stitt AW, Lois N, Medina RJ, et al., Advances in our understanding of diabetic retinopathy, *Clinical Science*, 2013;125:1–17.
- Tang J, Kern TS, Inflammation in diabetic retinopathy, *Prog Retin Eye Res*, 2011;30:343–58.
- Trapp V, Parmakhtiar B, Papazian V, et al., Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture, *Angiogenesis*, 2010;13:305–15.
- Kasiotis KM, Pratsinis H, Kletsas D, Haroutounian SA, Resveratrol and related stilbenes: Their anti-aging and anti-angiogenic properties, *Food Chem Toxicol*, 2013;61:112–20.
- Kubota S, Ozawa Y, Kurihara T, et al., Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation, *Invest Ophthalmol Vis Sci*, 2011;52:9142–8.
- Kim YH, Kim YS, Kang SS, et al., Resveratrol inhibits neuronal apoptosis and elevated Ca<sup>2+</sup>/calmodulin-dependent protein kinase II activity in diabetic mouse retina, *Diabetes*, 2010;59:1825–35.
- Soufi FG, Mohammed-Nejad D, Ahmadi H, Resveratrol improves diabetic retinopathy possibly through oxidative stress – nuclear factor  $\kappa$ B – apoptosis pathway, *Pharmacol Rep*, 2012;64:1505–14.
- Kim YH, Kim YS, Roh GS, et al., Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas, *Acta Ophthalmol*, 2012;90:e31–e37.
- Tian C, Zhang R, Ye X, et al., Resveratrol ameliorates high-glucose-induced hyperpermeability mediated by caveolae via VEGF/KDR pathway, *Genes Nutr*, 2013;8:231–9.
- Hua J, Guerin KJ, Chen J, et al., Resveratrol inhibits pathologic retinal neovascularization in Vldlr(??) mice, *Invest Ophthalmol Vis Sci*, 2011;52:2809–16.
- Almeida L, Vaz-da-Silva M, Falcao A, et al., Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers, *Mol Nutr Food*, 2009;53(Suppl. 1): S7–S15.
- Nunes T, Almeida L, Rocha JF, et al., Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects, *J Clin Pharmacol*, 2009;49:1477–82.